Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Net Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Net Margin for 13 consecutive years, with 243.87% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 7804.0% to 243.87% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 122.25% through Dec 2025, up 13746.0% year-over-year, with the annual reading at 98.5% for FY2025, 11370.0% up from the prior year.
  • Net Margin for Q4 2025 was 243.87% at Theravance Biopharma, up from 18.06% in the prior quarter.
  • The five-year high for Net Margin was 7445.92% in Q3 2022, with the low at 212.04% in Q1 2023.
  • Average Net Margin over 5 years is 429.06%, with a median of 37.18% recorded in 2021.
  • The sharpest move saw Net Margin surged 728977bps in 2022, then crashed -750295bps in 2023.
  • Over 5 years, Net Margin stood at 172.49% in 2021, then tumbled by -85bps to 26.58% in 2022, then plummeted by -282bps to 48.45% in 2023, then skyrocketed by 442bps to 165.84% in 2024, then skyrocketed by 47bps to 243.87% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 243.87%, 18.06%, and 209.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.